Form 4/A for ELVN Enliven Therapeutics, Inc.
Accepted 2021-07-23 00:00:00 ET · period of report 2021-07-16 · accession 0000947871-21-000797 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AI | 2021-07-23 | 2021-07-16 | ELVN | OrbiMed Capital GP VII LLC | Dir, 10% | P - Purchase | $6.00 | +1.67M | 4.20M | +66% | +$10.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-16 | P | A | 1,666,666 | $6.00 | 4,199,068 | I See footnotes | — | — | (F1) These shares of the Issuer's common stock ("Shares") were purchased in the Company's underwritten public offering. The previously reported acquisition of these Shares was inadvertently attributed to OrbiMed Partners Master Fund Limited. (F2) The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of GP VII. GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII. (F3) This report on Form 4 is filed by OrbiMed Advisors and GP VII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons, or David Bonita, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |